AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine by Seini Moimoi | May 3, 2024 | Portfolio News
Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3202 in Patients with Locally Advanced or Metastatic Melanoma by Seini Moimoi | May 2, 2024 | Portfolio News
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy by Seini Moimoi | Apr 17, 2024 | Portfolio News
Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting by Seini Moimoi | Apr 10, 2024 | Portfolio News
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency by Seini Moimoi | Apr 8, 2024 | Portfolio News
Cohere Health to Further Reduce Administrative Burden for Providers via Epic’s Payer Platform by Seini Moimoi | Apr 3, 2024 | Portfolio News
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome by Seini Moimoi | Apr 2, 2024 | Portfolio News
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis by Seini Moimoi | Mar 13, 2024 | Portfolio News
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing by Seini Moimoi | Mar 13, 2024 | Portfolio News
CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference by Seini Moimoi | Mar 7, 2024 | Portfolio News
